155 related articles for article (PubMed ID: 17355998)
21. Cataract surgery in diabetes mellitus: A systematic review.
Kelkar A; Kelkar J; Mehta H; Amoaku W
Indian J Ophthalmol; 2018 Oct; 66(10):1401-1410. PubMed ID: 30249823
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic Effects of a Novel Phenylphthalimide Analog for Corneal Neovascularization and Retinal Vascular Leakage.
Wang B; Li PK; Ma JX; Chen D
Invest Ophthalmol Vis Sci; 2018 Jul; 59(8):3630-3642. PubMed ID: 30029250
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of Macular Edema in Behcet Disease after Intravitreal Bevacizumab Injection.
Ghassemi F; Mirak SA; Chams H; Sabour S; Ahmadabadi MN; Davatchi F; Shahram F
J Ophthalmic Vis Res; 2017; 12(1):44-52. PubMed ID: 28299006
[TBL] [Abstract][Full Text] [Related]
24. Office-based Management of Recurrent Respiratory Papilloma.
Motz KM; Hillel AT
Curr Otorhinolaryngol Rep; 2016 Jun; 4(2):90-98. PubMed ID: 27242951
[TBL] [Abstract][Full Text] [Related]
25. Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain.
Hamilton JL; Nagao M; Levine BR; Chen D; Olsen BR; Im HJ
J Bone Miner Res; 2016 May; 31(5):911-24. PubMed ID: 27163679
[TBL] [Abstract][Full Text] [Related]
26. Combination of Aflibercept and Bromfenac Therapy in Age-Related Macular Degeneration: A Pilot Study Aflibercept and Bromfenac in AMD.
Wyględowska-Promieńska D; Piotrowska-Gwóźdź A; Piotrowska-Seweryn A; Mazur-Piotrowska G
Med Sci Monit; 2015 Dec; 21():3906-12. PubMed ID: 26667262
[TBL] [Abstract][Full Text] [Related]
27. Photothrombosis of corneal neovascularization by photodynamic therapy utilizing verteporfin and diode laser.
Ahmed Hassan A; Foad Ghoneim D; Abdelraheem El-Dib A; Abdelkawi Ahmed S; Abdel-Salam AM
J Lasers Med Sci; 2013; 4(3):131-9. PubMed ID: 25606321
[TBL] [Abstract][Full Text] [Related]
28. The effects of intravitreal bevacizumab in infectious and noninfectious uveitic macular edema.
Al-Dhibi H; Hamade IH; Al-Halafi A; Barry M; Chacra CB; Gupta V; Tabbara KF
J Ophthalmol; 2014; 2014():729465. PubMed ID: 25136452
[TBL] [Abstract][Full Text] [Related]
29. The methodological quality of systematic reviews comparing intravitreal bevacizumab and alternates for neovascular age related macular degeneration: A systematic review of reviews.
George PP; DeCastro Molina JA; Heng BH
Indian J Ophthalmol; 2014 Jul; 62(7):761-7. PubMed ID: 25116765
[TBL] [Abstract][Full Text] [Related]
30. Combination of bevacizumab and bromfenac therapy in age-related macular degeneration: a pilot study.
Wyględowska-Promieńska D; Piotrowska-Gwóźdź A; Piotrowska-Seweryn A; Mazur-Piotrowska G; Rokicki W
Med Sci Monit; 2014 Jul; 20():1168-75. PubMed ID: 25006692
[TBL] [Abstract][Full Text] [Related]
31. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
Braithwaite T; Nanji AA; Lindsley K; Greenberg PB
Cochrane Database Syst Rev; 2014 May; 2014(5):CD007325. PubMed ID: 24788977
[TBL] [Abstract][Full Text] [Related]
32. Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo.
Rauck BM; Friberg TR; Medina Mendez CA; Park D; Shah V; Bilonick RA; Wang Y
Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):469-76. PubMed ID: 24370837
[TBL] [Abstract][Full Text] [Related]
33. Combined therapy for diabetic macular edema.
Al Rashaed S; Arevalo JF
Middle East Afr J Ophthalmol; 2013; 20(4):315-20. PubMed ID: 24339681
[TBL] [Abstract][Full Text] [Related]
34. Cataracts in diabetic patients: a review article.
Javadi MA; Zarei-Ghanavati S
J Ophthalmic Vis Res; 2008 Jan; 3(1):52-65. PubMed ID: 23479523
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion.
Shahsuvaryan ML
Int J Ophthalmol; 2012; 5(6):759-70. PubMed ID: 23275914
[TBL] [Abstract][Full Text] [Related]
36. Comparison of systemic adverse events associated with intravitreal anti-VEGF injection: ranibizumab versus bevacizumab.
Hwang DJ; Kim YW; Woo SJ; Park KH
J Korean Med Sci; 2012 Dec; 27(12):1580-5. PubMed ID: 23255862
[TBL] [Abstract][Full Text] [Related]
37. Characterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab.
Wen H; Hao J; Li SK
J Pharm Sci; 2013 Mar; 102(3):892-903. PubMed ID: 23212655
[TBL] [Abstract][Full Text] [Related]
38. Fluid pressure is a magnitude-dependent modulator of early endothelial tubulogenic activity: implications related to a potential tissue-engineering control parameter.
Shin HY; Underwood RM; Fannon MW
Tissue Eng Part A; 2012 Dec; 18(23-24):2590-600. PubMed ID: 22793042
[TBL] [Abstract][Full Text] [Related]
39. The subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesis.
Tunik S; Nergiz Y; Keklikci U; Akkus M
Graefes Arch Clin Exp Ophthalmol; 2012 Aug; 250(8):1161-7. PubMed ID: 22527313
[TBL] [Abstract][Full Text] [Related]
40. [Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession].
Janzen RW; Ludwig WD;
Z Rheumatol; 2012 Feb; 71(2):108-10, 112-8. PubMed ID: 22370801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
